Reported 9 days ago
Eli Lilly has seen significant success with its weight loss drugs, Mounjaro and Zepbound, but emerging biotech company Viking Therapeutics is gaining attention with promising results from its weight loss candidate VK2735. Despite Eli Lilly's strong market presence and resources, the growing demand for weight loss medications indicates there might be room for multiple players, including Viking. Investors may choose to stick with the stability of Lilly, or take a risk on Viking's dynamic potential as it prepares for future trials.
Source: YAHOO